225Research

225Research strives to find strong investment opportunities and aims to provide in-depth and insightful analysis of these opportunities for our readers.

February 2023
M T W T F S S
 12345
6789101112
13141516171819
20212223242526
2728  

Disclaimer

The information found on “The Stock Boys” is for informational purposes only. It should not be taken or used as financial advice. The Stock Boys makes no guarantee or promises as to any results that may be obtained from using our content. No one should make any investment decision based solely on the information found on this site and without the help of a financial adviser or conduction of their own research and due diligence. The Stock Boys disclaim any liability for any results incurred by the use of our information, content or articles. Your use of the information of materials linked from the site is at your own risk.

February 2023
M T W T F S S
 12345
6789101112
13141516171819
20212223242526
2728  

Disclaimer

The information found on “The Stock Boys” is for informational purposes only. It should not be taken or used as financial advice. The Stock Boys makes no guarantee or promises as to any results that may be obtained from using our content. No one should make any investment decision based solely on the information found on this site and without the help of a financial adviser or conduction of their own research and due diligence. The Stock Boys disclaim any liability for any results incurred by the use of our information, content or articles. Your use of the information of materials linked from the site is at your own risk.

Equity Report Our Picks

Bausch Health

Download the full Bausch Health Report

Bausch Health (formerly known as Valeant) is a Canadian based company headquartered in Laval Quebec. The company we know today was a direct result of a series of acquisitions, cutting R&D, and raising prices to grow the top and bottom line impressively. This came to an end in 2015, when the stock and company came crashing down amid short sellers over their price gouging, debt burden and potential of fraud with one of their units, Philidor. After this, out went CEO Mike Pearson and in came Joseph Papa and the company began to run like a typical pharma company, spending more on R&D and attempting to correct the balance sheet. Although just a shell of what it once was, the company possesses a diversified business with Salix (GI Tract), Bausch and Lomb (Prescription and OTC eye care products/equipment), ortho/dermatology, and a slew of other diversified products including Neuro, that provides the company with steady, strong cash flows.

The company continues to execute upon their plan, yet the market refuses to reward the company with a multiple anywhere close to peers. In the long term, we believe that for a multitude of reasons such as rightsizing the balance sheet, pipeline breadth, and strong cash flows, the company should start to be rewarded with a closer valuation to peers.

Download the full Bausch Health Report